Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France

  title={Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France},
  author={Gilles Pialoux and Anne-genevi{\`e}ve Marcelin and Nicolas Despi{\'e}gel and Caroline Espinas and H{\'e}l{\`e}ne Cawston and Laurent Finkielsztejn and Audrey Laurisse and C{\'e}line Aubin and Cristian Apetrei},
  booktitle={PloS one},
OBJECTIVES To evaluate the cost-effectiveness of a new generation integrase inhibitor (INI), dolutegravir (DTG), in France, in treatment-experienced (TE) and INI-naïve HIV-infected adults with at least two classes resistance compared to raltegravir (RAL), by adapting previously published Anti-Retroviral Analysis by Monte Carlo Individual Simulation (ARAMIS) model. METHODS ARAMIS is a microsimulation Markov model with a lifetime time horizon and a monthly cycle length. Health states are… CONTINUE READING
2 Extracted Citations
31 Extracted References
Similar Papers

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 31 references

Final 5-Year Results of the BENCHMRK Studies: Sustained Antiretroviral Effect of Raltegravir, and Exploratory Analysis of Late Outcomes Based on Early Virologic Response

  • JJ Eron, DA Cooper, +5 authors editors
  • XIX International AIDS Conference;
  • 2012
Highly Influential
5 Excerpts

Assessment of real-life predictive power of a new cost-effectiveness model in HIV: antiretroviral analysis by Monte Carlo individual simulation (ARAMIS-DTG)—PIN

  • N Despiégel, D Anger, +5 authors editors
  • PLOS ONE | DOI:10.1371/journal.pone.0145885…
  • 2014
1 Excerpt

Prise en charge médicale des personnes vivant avec le VIH—Actualisation 2014 du Rapport 2013—Sous la direction du Pr Phillipe

  • P. Morlat
  • Morlat et sous l'égide du CNS et de l'ANRS 2014…
  • 2014
2 Excerpts

Similar Papers

Loading similar papers…